Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
Oncology (Williston Park). 2009 Dec;23(14):1276-81.
Hepatocellular cancer (HCC) is a major cause of mortality. Management approaches including surgical and locoregional strategies such as transarterial chemoembolization, radiofrequency ablation, ethanol injections, transarterial chemotherapy infusion, and systemic chemotherapy have proved to be disappointing. Orthotopic liver transplantation (OLT) continues to give patients the best chance for cure, but recurrence of the disease remains a problem. Several investigators have looked into the value of adjuvant chemotherapy in HCC with or without other local neoadjuvant treatment modalities after OLT. Studies have looked at various treatment modalities, but overall results have been disappointing. No adjuvant treatment is currently advocated after OLT in HCC. This review summarizes the current data on efficacy and rationale of adjuvant treatment for HCC after OLT, as well as future prospects.
肝细胞癌 (HCC) 是主要的死亡原因。管理方法包括手术和局部区域策略，如经动脉化疗栓塞、射频消融、乙醇注射、经动脉化疗输注和全身化疗，已被证明令人失望。原位肝移植 (OLT) 仍然为患者提供了最好的治愈机会，但疾病的复发仍然是一个问题。一些研究人员研究了辅助化疗在 OLT 前后联合或不联合其他局部新辅助治疗方法对 HCC 的价值。研究已经研究了各种治疗方法，但总体结果令人失望。目前在 HCC 患者接受 OLT 后不提倡辅助治疗。本综述总结了 OLT 后 HCC 辅助治疗的疗效和原理的最新数据，以及未来的前景。
